Ageing and death have for long held people captive in fear. This fear has raked in thousands for plastic surgeons and companies lauding products and processes that will prolong your life or, at the very least, your health. It is out of this fear that the company Ambrosia, a startup that offered transfusions of human plasma harvested from young donors from the age of 16 and 25 years, to clients 30 years or older, managed to stay in business for a year-and-a-half before closing its doors. Its claims that the process could improve health ailments and extend a person’s life were controversial and unproven. Earlier in 2019, the startup closed its doors after the American Food and Drug Administration (FDA) issued a warning to potential customers, citing public health concerns and informing them that these treatments had not undergone FDA testing and should be assumed to be unsafe and ineffective. The cohorts who were willing to pay more than R113,000 for one litre of young blood will rejo...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now